Clinical Research Trials
Nonalcoholic Fatty Liver Disease (NAFLD) Patient Registry
One of the many consequences of the obesity epidemic facing the United States and other developed countries is the increased prevalence of NAFLD. NAFLD includes a spectrum of disorders ranging from simple steatosis to NASH (Nonalcoholic steatohepatitis), with the possibility of progression to cirrhosis and liver cancer.
There is still much more to be known about these disorders. This prospective study will follow patients with NAFLD every 6 months, collecting clinical data, serum, whole blood, and tissue from patients with NAFLD. With these data, we hope to learn more about its natural history and risk factors for progression and to develop noninvasive tests to diagnose Nonalcoholic steatohepatitis (NASH), a more serious and progressive condition.
For more information please email Michelle Lai, MD, MPH or Angelica Francescucci,CRA
A Prospective Study of Patterns, Predictors, and Mechanisms of Weight Loss with Exenatide Treatment in Overweight and Obese Women without Diabetes
This study looks at the effects of a medication and/or a low-calorie diet on body weight and energy expenditure. The medication is called exenatide (brand name Byetta). Exenatide is an injectable medication that is approved by the FDA for the treatment of type 2 diabetes. It is not approved for the treatment of obesity. Exentide has shown to have several effects on the body including decreased hunger, and the slowing of gastric (stomach) emptying.
At all study visits, you will have weight, blood pressure, waist circumference, and body composition measured. You will also be asked to complete questionnaires about hunger, fullness and nausea. At some study visits, you will have blood drawn to measure markers of metabolism and inflammation. You may also be asked to have your energy expenditure measured at these study visits. Compensation will be provided for participating and subjects will receive a parking voucher at all study visits.
For more information, please email Jody Dushay, MD.